The Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG

Algeta ASA: The Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG

  • In response to recent media commentary, the Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG. 

  • The commentary in the media refers to an acquisition proposal at a price of NOK 306 per Algeta share. This is incorrect. The preliminary acquisition proposal is NOK 336 per Algeta share. 

  • There is no certainty that this preliminary acquisition proposal will lead to a transaction or as to the terms of any such transaction.

Oslo, Norway, 26 November, 2013 - The Board of Directors of Algeta ASA (OSE: ALGETA) today announced that it is in receipt of a preliminary acquisition proposal from Bayer AG which may or may not lead to a transaction. Discussions are at an early stage and further announcements may be made, as appropriate, in due course.

###

For further information, please contact:

Oystein Soug +47 90 65 65 25
CFO  
   
Mike Booth +1 646 410 1884
Communications & Corporate Affairs [email protected]
   

About Algeta

Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.